Amy­lyx's ALS drug sales beat Wall Street ex­pec­ta­tions in first full quar­ter

The sales num­bers are in for Amy­lyx’s first full quar­ter as a com­mer­cial-stage biotech, and by and large they beat the Street’s ex­pec­ta­tions.

Amy­lyx’s ALS drug Re­lyvrio pulled in near­ly $22 mil­lion in the fourth quar­ter of last year, sur­pass­ing an­a­lyst es­ti­mates and sug­gest­ing high de­mand from pa­tients and ad­vo­cates’ long-run­ning cam­paign lead­ing up to last Sep­tem­ber’s ap­proval. SVB Se­cu­ri­ties’ Marc Good­man wrote last month the sales con­sen­sus was about $4 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER